[go: up one dir, main page]

PT2399582E - Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos - Google Patents

Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos Download PDF

Info

Publication number
PT2399582E
PT2399582E PT111749305T PT11174930T PT2399582E PT 2399582 E PT2399582 E PT 2399582E PT 111749305 T PT111749305 T PT 111749305T PT 11174930 T PT11174930 T PT 11174930T PT 2399582 E PT2399582 E PT 2399582E
Authority
PT
Portugal
Prior art keywords
dhea
dehydroepiandrosterone
analogues
combination
estrogen receptor
Prior art date
Application number
PT111749305T
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of PT2399582E publication Critical patent/PT2399582E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
PT111749305T 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos PT2399582E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/096,284 US6465445B1 (en) 1998-06-11 1998-06-11 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Publications (1)

Publication Number Publication Date
PT2399582E true PT2399582E (pt) 2014-06-25

Family

ID=22256661

Family Applications (4)

Application Number Title Priority Date Filing Date
PT111749255T PT2386304E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos
PT50181155T PT1623712E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com a dehidroepiandrosterona (dhea) ou análogos
PT111749305T PT2399582E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos
PT111749339T PT2386305E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com a dehidroepiandrosterona (dhea) ou análogos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT111749255T PT2386304E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com deidroepiandrosterona (dhea) ou análogos
PT50181155T PT1623712E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com a dehidroepiandrosterona (dhea) ou análogos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT111749339T PT2386305E (pt) 1998-06-11 1999-06-10 Modulador seletivo do recetor de estrogénio em combinação com a dehidroepiandrosterona (dhea) ou análogos

Country Status (29)

Country Link
US (6) US6465445B1 (pt)
EP (5) EP2386304B9 (pt)
JP (3) JP2002517433A (pt)
KR (6) KR20090016771A (pt)
CN (2) CN1240388C (pt)
AR (1) AR043075A1 (pt)
AT (1) ATE308326T1 (pt)
AU (1) AU4253099A (pt)
BR (1) BR9911116A (pt)
CA (7) CA2768682C (pt)
CY (4) CY1113712T1 (pt)
DE (1) DE69928104T2 (pt)
DK (5) DK1623712T3 (pt)
ES (5) ES2458218T3 (pt)
HK (1) HK1040367B (pt)
HU (2) HU230495B1 (pt)
ID (1) ID28696A (pt)
IL (3) IL140178A0 (pt)
MX (1) MXPA00012306A (pt)
MY (3) MY157030A (pt)
NO (2) NO331022B1 (pt)
NZ (1) NZ508801A (pt)
PL (4) PL203343B1 (pt)
PT (4) PT2386304E (pt)
RU (1) RU2246947C2 (pt)
TR (5) TR200103454T2 (pt)
TW (2) TWI371279B (pt)
WO (1) WO1999063974A2 (pt)
ZA (1) ZA200007297B (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1104414B1 (en) * 1998-08-14 2003-02-12 Schering Corporation Enantioselective synthesis
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
AU2156800A (en) * 1998-12-18 2000-07-12 Schering Corporation Oral antiestrogen pharmaceutical composition
KR20020011437A (ko) 1999-06-11 2002-02-08 추후보정 여성에 비-경구 안드로겐형 스테로이드의 투여
TR200502284T2 (tr) 1999-07-06 2005-08-22 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
JP4896335B2 (ja) * 2000-03-01 2012-03-14 ナームローゼ・フエンノートチヤツプ・オルガノン エストロゲン化合物としてのクロマン誘導体
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
JP2004502734A (ja) * 2000-07-06 2004-01-29 ワイス 一酸化窒素シンターゼ活性の増強方法
EP1299093A2 (en) * 2000-07-06 2003-04-09 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003988A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
MXPA03001245A (es) * 2000-08-11 2003-05-27 Wyeth Corp Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
FR2827764B1 (fr) * 2001-07-27 2005-08-19 Oreal Composition, notamment cosmetique, renfermant un steroide et un glycol
CZ2004118A3 (cs) 2001-07-31 2004-09-15 Pfizer Products Inc. Farmaceutický prostředek, kit a způsoby zahrnující kombinaci činidla estrogenový agonist/antagonist, estrogenu a progestinu
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
PT1501819E (pt) * 2002-04-24 2010-11-11 Merck Sharp & Dohme Moduladores dos receptores de estrogéneo
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
JP2007503810A (ja) * 2003-08-26 2007-03-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エストロゲンレセプターモジュレーターおよびそれらの使用
NZ553834A (en) 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8941594B2 (en) * 2004-10-01 2015-01-27 Nvidia Corporation Interface, circuit and method for interfacing with an electronic device
AU2005297367B2 (en) * 2004-10-20 2010-02-04 Myriel Pharmaceuticals, Llc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
DE602006006432D1 (de) 2005-03-24 2009-06-04 Nolabs Ab Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür
RU2297798C1 (ru) * 2005-10-03 2007-04-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук ГУ НИИ онкологии ТНЦ СО РАМН Способ комплексного лечения резектабельных форм рака эндометрия
CN101448490A (zh) 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
AU2007256718A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
SI2121553T1 (sl) 2007-02-14 2012-11-30 Hormos Medical Ltd Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
RU2384894C1 (ru) * 2008-10-27 2010-03-20 Леонид Борисович Лазебник Способ моделирования остеопороза
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US20120142645A1 (en) * 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
KR101731008B1 (ko) * 2010-06-16 2017-04-27 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
ES2773732T3 (es) 2010-11-01 2020-07-14 Mei Pharma Inc Composiciones de isoflavonoides y procedimientos para el tratamiento del cáncer
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
EP2729131B1 (en) 2011-07-05 2020-04-15 Novan, Inc. Topical compositions
ES2545337T3 (es) * 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Comprimido que contiene dehidroepiandrosterona (DHEA)
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
MX2016001901A (es) 2013-08-12 2016-10-13 Tokai Pharmaceuticals Inc Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
EP3698775A1 (en) 2014-07-11 2020-08-26 Novan Inc. Topical antiviral compositions and methods of using the same
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
MX381863B (es) 2015-02-02 2025-03-13 Mei Pharma Inc Terapias de combinación.
US10452661B2 (en) * 2015-06-18 2019-10-22 Microsoft Technology Licensing, Llc Automated database schema annotation
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR102319497B1 (ko) 2016-03-02 2021-11-01 노반, 인크. 염증 치료용 조성물 및 염증 치료 방법
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
CN109310630A (zh) 2016-04-13 2019-02-05 诺万公司 用于治疗感染的组合物、系统、试剂盒和方法
FR3052805B1 (fr) 2016-06-20 2020-06-26 Safran Aircraft Engines Disque aubage monobloc ameliore, partie tournante d'une turbomachine comprenant un tel disque et turbomachine associee
CN109224029A (zh) * 2018-09-30 2019-01-18 泓博元生命科技（深圳）有限公司 含有nmn的降血脂组合物、制剂及其制备方法与应用
EP4038147A4 (en) * 2019-10-03 2024-02-07 Caren Pharmaceuticals, Inc. COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
AU2021314955A1 (en) 2020-07-28 2023-03-30 Jazz Pharmaceuticals Ireland Limited Fused bicyclic Raf inhibitors and methods for use thereof
AU2023222260A1 (en) * 2022-02-17 2024-10-03 Debreceni Egyetem Dhea-derived steroids
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US536220A (en) * 1895-03-26 Puzzle
DK122125B (da) 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4496556A (en) 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
AU594309B2 (en) 1984-08-02 1990-03-08 Fernand Labrie Pharmaceutical composition for combination therapy of hormonedependent cancers
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
JP2551590B2 (ja) * 1987-06-26 1996-11-06 株式会社リコー 複写機光学系の速度制御方法
JPS6440428A (en) 1987-08-07 1989-02-10 Daiichi Yakuhin Sangyo Kk Antihyperlipemia
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
HU208150B (en) 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
US5686465A (en) 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
ZA899112B (en) 1988-12-01 1990-08-29 Schering Corp Compositions for transdermal delivery of estradiol
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
ATE128362T1 (de) 1989-03-10 1995-10-15 Endorecherche Inc Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
HUT64815A (en) 1992-09-04 1994-03-28 Berki An external correcting and fixing apparatus for treatment of fractures and defomities of bones as well as correcting unit preferably for external correcting and fixing units
US5354861A (en) 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
AU686120B2 (en) * 1993-01-19 1998-02-05 Endorecherche Inc. Therapeutic methods & delivery systems utilizing sex steroid precursors and novel steroidal derivatives and pharmaceutical compositions thereof
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4401554A1 (de) 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
CZ285522B6 (cs) 1993-06-24 1999-08-11 Eli Lilly And Company Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
US5441964A (en) 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5418252A (en) 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5482950A (en) 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5446061A (en) 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
PT654267E (pt) 1993-11-19 2002-09-30 Jenapharm Gmbh Carcinoestaticos para terapia hormonal contendo dienogest como componente eficaz
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5425429A (en) * 1994-06-16 1995-06-20 Thompson; Michael C. Method and apparatus for forming lateral boreholes
US5681308A (en) 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
NZ272608A (en) 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
US5502074A (en) 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
IL115022A (en) 1994-08-22 2000-07-31 Lilly Co Eli Pharmaceutical compositions for inhibiting endometrial cancer
US5550123A (en) 1994-08-22 1996-08-27 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
EP0769946A4 (en) 1994-08-22 1997-11-05 Lilly Co Eli METHOD FOR MAINTAINING THE TEETH AND BONE IN THE ORAL AREA
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6399634B1 (en) 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US5637598A (en) 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
HUT77603A (hu) 1994-11-29 1998-06-29 Hoechst Marion Roussel Inc. Triaril-etilén-származékok felhasználása oszteoporózis kezelésére és megelőzésére alkalmas gyógyszerkészítmény előállítására
JPH10511961A (ja) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 高リポプロテイン血症、高トリグリセリド血症、高脂血症又は高コレステロール血症の治療又は予防のための、又は抗血液凝固処置のための医薬組成物の製造のための３，４−ジフェニル・クロマンの使用
US5489587A (en) 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5571808A (en) 1995-01-31 1996-11-05 Eli Lilly And Company Method for treating smoking-related bone loss
US5552401A (en) 1995-02-28 1996-09-03 Eli Lilly And Company 2-benzyl-3-arylbenzothiophenes
US5523309A (en) 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
DK0747056T3 (da) * 1995-06-06 2000-05-01 Lilly Co Eli Minimering af knogletab med anti-estrogenkombinationer
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
ES2124064T3 (es) 1995-06-07 1999-01-16 Lilly Co Eli Compuestos y composiciones con cadenas laterales nitrogenadas no basicas.
CA2241462A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
HUP9902683A3 (en) 1996-01-11 2001-08-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
WO1997030069A1 (en) * 1996-02-14 1997-08-21 Hoechst Marion Roussel, Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and c17-20-lyase
US6432982B1 (en) 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
IL125863A (en) 1996-02-22 2000-10-31 Lilly Co Eli Benzothiophenes and formulations containing same
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1997032837A1 (en) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Nonsteroidal estrogen derivatives
EP0801066A1 (en) 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
EP0925064B1 (en) * 1996-04-11 2003-06-25 LORIA, Roger M. 5-ANDROSTENE 3 beta,17alpha DIOL AS AN INHIBITOR OF TUMOR GROWTH
EP0802183B1 (en) 1996-04-19 2001-10-10 American Home Products Corporation Estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
GB9616700D0 (en) * 1996-08-09 1996-09-25 Carey Beverly J Hormone supplement
HUP0001172A3 (en) * 1996-08-28 2002-01-28 Lilly Co Eli Amorphous benzothiophenes, methods of preparation, and methods of use
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
CN1250373A (zh) * 1997-02-07 2000-04-12 瑟垃技术有限公司 用于在具有睾酮缺乏症状的妇女中补充睾酮的组合物和方法
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ZA985543B (en) * 1997-06-27 1998-12-28 Smithkline Beecham Corp Novel methods
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
GEP20033079B (en) 1998-05-15 2003-10-27 Wyeth Corp Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
KR100679735B1 (ko) * 1998-06-11 2007-02-07 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물및 그 용도
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
HUP9900284A2 (hu) 1999-02-09 2001-02-28 János Váradi Háromfázisú, hidraulikus rugózó elem közúti és vasúti járművek számára
TR200502284T2 (tr) 1999-07-06 2005-08-22 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
AU2005297367B2 (en) * 2004-10-20 2010-02-04 Myriel Pharmaceuticals, Llc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
US7884092B2 (en) 2011-02-08
KR100944261B1 (ko) 2010-02-24
PT2386304E (pt) 2014-05-26
ES2463868T9 (es) 2014-06-24
JP2013049703A (ja) 2013-03-14
NZ508801A (en) 2003-08-29
CN1636566A (zh) 2005-07-13
US20040157812A1 (en) 2004-08-12
ES2458218T9 (es) 2014-06-24
CA2334577C (en) 2008-08-05
ZA200007297B (en) 2002-02-08
CA2768828A1 (en) 1999-12-16
AU4253099A (en) 1999-12-30
PL203343B1 (pl) 2009-09-30
JP2002517433A (ja) 2002-06-18
EP2386305B1 (en) 2014-02-12
IL140178A (en) 2008-07-08
CA2768682A1 (en) 1999-12-16
TR200103453T2 (tr) 2002-06-21
NO331022B1 (no) 2011-09-12
NO332187B1 (no) 2012-07-23
ES2463868T3 (es) 2014-05-29
ID28696A (id) 2001-06-28
ES2399051T3 (es) 2013-03-25
EP2386304A2 (en) 2011-11-16
CY1115317T1 (el) 2017-01-04
TR200103456T2 (tr) 2002-06-21
EP2399582A1 (en) 2011-12-28
HUP0103345A2 (hu) 2002-02-28
CY1115231T1 (el) 2017-01-04
PL345887A1 (en) 2002-01-14
TWI258369B (en) 2006-07-21
NO20092730L (no) 2001-02-01
EP2399582B1 (en) 2014-03-26
CA2768841C (en) 2013-08-13
BR9911116A (pt) 2001-02-28
HK1040367A1 (en) 2002-06-07
HUP0103345A3 (en) 2002-11-28
PT1623712E (pt) 2013-02-13
US7429576B2 (en) 2008-09-30
TR200100551T2 (tr) 2001-07-23
US6465445B1 (en) 2002-10-15
EP1623712A2 (en) 2006-02-08
ATE308326T1 (de) 2005-11-15
TW200810763A (en) 2008-03-01
CA2768773C (en) 2013-08-13
CA2768828C (en) 2013-08-13
DK2386305T3 (da) 2014-04-14
DK2386304T3 (da) 2014-05-12
KR20090018870A (ko) 2009-02-23
CA2768841A1 (en) 1999-12-16
EP2386305A2 (en) 2011-11-16
DE69928104D1 (de) 2005-12-08
DE69928104T2 (de) 2006-08-24
EP2386304B1 (en) 2014-03-19
EP1083905B1 (en) 2005-11-02
KR20090018227A (ko) 2009-02-19
US20070027124A1 (en) 2007-02-01
CN1312718A (zh) 2001-09-12
KR20090016771A (ko) 2009-02-17
US7943603B2 (en) 2011-05-17
HU1600307D0 (hu) 2002-02-28
CY1113712T1 (el) 2016-06-22
DK2399582T3 (da) 2014-07-07
WO1999063974A2 (en) 1999-12-16
TWI371279B (en) 2012-09-01
ES2458218T3 (es) 2014-04-30
ES2253922T3 (es) 2006-06-01
TR200103455T2 (tr) 2002-06-21
CN1240388C (zh) 2006-02-08
US6670346B1 (en) 2003-12-30
ES2473040T3 (es) 2014-07-03
MY151187A (en) 2014-04-30
CA2632567C (en) 2012-04-10
KR20090018871A (ko) 2009-02-23
NO20006254D0 (no) 2000-12-08
US8188066B2 (en) 2012-05-29
AR043075A1 (es) 2005-07-20
DK1623712T3 (da) 2013-01-21
EP1623712A3 (en) 2009-12-16
US20070027122A1 (en) 2007-02-01
EP2386305B9 (en) 2014-12-17
EP1083905A2 (en) 2001-03-21
IL185087A0 (en) 2007-12-03
RU2246947C2 (ru) 2005-02-27
TR200103454T2 (tr) 2002-06-21
PL195772B1 (pl) 2007-10-31
HU230495B1 (hu) 2016-09-28
NO20006254L (no) 2001-02-01
EP2386304B9 (en) 2014-11-05
IL140178A0 (en) 2002-02-10
CA2632567A1 (en) 1999-12-16
MY125047A (en) 2006-07-31
PL199798B1 (pl) 2008-10-31
KR20010052763A (ko) 2001-06-25
PL203704B1 (pl) 2009-11-30
EP2386305A3 (en) 2011-12-07
CA2768882A1 (en) 1999-12-16
HK1040367B (zh) 2006-09-29
WO1999063974A3 (en) 2000-06-29
DK1083905T3 (da) 2006-03-20
EP1623712B1 (en) 2012-12-12
CY1115069T1 (el) 2016-12-14
EP2399582B9 (en) 2014-09-10
CA2768682C (en) 2014-03-18
US20070027123A1 (en) 2007-02-01
MXPA00012306A (es) 2003-07-28
JP2007191484A (ja) 2007-08-02
PT2386305E (pt) 2014-04-17
MY157030A (en) 2016-04-15
KR20090018226A (ko) 2009-02-19
CA2334577A1 (en) 1999-12-16
CA2768773A1 (en) 1999-12-16
CA2768882C (en) 2015-01-27
EP2386304A3 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
PT1623712E (pt) Modulador seletivo do recetor de estrogénio em combinação com a dehidroepiandrosterona (dhea) ou análogos
IL149990A0 (en) Selective estrogen receptor modulators in combination with estrogens
HUP0204029A3 (en) Triphenylalkene derivatives and their use as selective estrogen receptor modulators
GB2353527B (en) Adenosine A3 receptor modulators
GB9709183D0 (en) Bus connectuon set up and tear down
IL120262A (en) Droloxifene and derivatives thereof for use in increasing serum testosterone levels
SI1076558T1 (en) 2-phenyl-1-(-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MXPA01011294A (es) Compuestos moduladores de receptor de progesterona tetraciclicos y metodos.
IL139588A0 (en) Teerapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
AP2002002475A0 (en) Hormonal composition based on a progesterone and an oestrogen and use thereof
IL139386A0 (en) Dhea composition and method
HK1032007A (en) Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
GB9807575D0 (en) A seat arrangement and harness therefor
GB9913649D0 (en) Estrogen receptor
GB9820323D0 (en) Mixing and anti bridging device
SI1235776T1 (sl) Trifenilalkenski derivati in njihova uporaba kot selektivni estrogenski receptorski modulatorji
TWI293247B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors (2)
ZA98432B (en) Cargo securing device
GB9707500D0 (en) Improvements in devices for securing probes
GB9803202D0 (en) Estrogen Receptor Ligands
GB9803061D0 (en) Estrogen receptor ligands
GB9825709D0 (en) Cargo holding device
MXPA01011290A (es) Benzimidazolonas y analogos y su uso como ligandos de receptor de progesterona.
IL139493A0 (en) Adenosine a3 receptor modulators
IL156851A0 (en) Adenosine a3 receptor modulators